First Time Loading...

Ascletis Pharma Inc
HKEX:1672

Watchlist Manager
Ascletis Pharma Inc Logo
Ascletis Pharma Inc
HKEX:1672
Watchlist
Price: 1.4 HKD 7.69% Market Closed
Updated: May 3, 2024
Section:
 

Wall Street
Price Targets

Price Targets Summary
Ascletis Pharma Inc

Wall Street analysts forecast Ascletis Pharma Inc stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Ascletis Pharma Inc is 3.04 HKD with a low forecast of 2.18 HKD and a high forecast of 3.99 HKD.

Lowest Forecast
Wall Street Target
2.18 HKD
56% Upside
Average Forecast
Wall Street Target
3.04 HKD
117% Upside
Highest Forecast
Wall Street Target
3.99 HKD
185% Upside
Lowest
Price Target
2.18 HKD
56% Upside
Average
Price Target
3.04 HKD
117% Upside
Highest
Price Target
3.99 HKD
185% Upside
Ascletis Pharma Inc Competitors:
Price Targets
OXB
Oxford BioMedica PLC
31% Upside
300653
Yantai Zhenghai Bio-Tech Co Ltd
41% Upside
1530
3SBio Inc
16% Upside
MRSN
Mersana Therapeutics Inc
104% Upside
OXB
Oxford BioMedica PLC
31% Upside
300653
Yantai Zhenghai Bio-Tech Co Ltd
41% Upside
1530
3SBio Inc
16% Upside
MRSN
Mersana Therapeutics Inc
104% Upside
300685
Amoy Diagnostics Co Ltd
30% Upside
LVTX
LAVA Therapeutics NV
124% Upside
A
AELIS
Aelis Farma SA
62% Upside
3164
GenMont Biotech Inc
340% Upside

Revenue
Forecast

Revenue Estimate
Ascletis Pharma Inc

For the last 6 years the compound annual growth rate for Ascletis Pharma Inc's revenue is 1%. The projected CAGR for the next 3 years is -1%.

1%
Past Growth
-1%
Estimated Growth
Estimates Accuracy
-25%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Ascletis Pharma Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Ascletis Pharma Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
88%
Average Beat
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Ascletis Pharma Inc's stock price target?
Price Target
3.04 HKD

According to Wall Street analysts, the average 1-year price target for Ascletis Pharma Inc is 3.04 HKD with a low forecast of 2.18 HKD and a high forecast of 3.99 HKD.

What is Ascletis Pharma Inc's Revenue forecast?
Projected CAGR
-1%

For the last 6 years the compound annual growth rate for Ascletis Pharma Inc's revenue is 1%. The projected CAGR for the next 3 years is -1%.

ALPHA SPREAD
Join more than 133,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.